Pharmaceutical

NICE recommends Rhythm’s Imcivree for rare genetic obesity disorder

Rhythm expects Imcivree will be available on the NHS in England and Wales within the next three months.

May 23, 2024 - 04:00
NICE recommends Rhythm’s Imcivree for rare genetic obesity disorder
Rhythm expects Imcivree will be available on the NHS in England and Wales within the next three months.
Read the original article

Tags:

Previous Article

AstraZeneca makes another obesity play funnelling $80m into SixPeaks Bio

Next Article

No nitrosamines: How parenteral packaging is evolving to meet today’s E&L challe...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Allogene to pursue new strategy for development of off-the-shelf cell therapy in blood cancer

STAT+: Allogene to pursue new strategy for development ...

Jan 4, 2024

Tevogen to go public in $1.2bn SPAC deal

Tevogen to go public in $1.2bn SPAC deal

Jun 29, 2023

What the end of affirmative action means to a fourth-year medical student

What the end of affirmative action means to a fourth-ye...

Jul 4, 2023